Merck Arcoxia User Fee Date Is Nov. 13; Schering’s Late Fees For Zetia Delay Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Arcoxia user fee deadline is two weeks later than expected; FDA considers NDA submission date to be Jan. 13, the day Schering paid outstanding product fees for Zetia.
You may also be interested in...
Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.
Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.
Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004
The revised guidance is primarily related to the performance of Merck's coxib franchise in overseas markets. A potential fourth quarter U.S. launch of Arcoxia is not included in the guidance.